Revista Portuguesa De Cardiologia最新文献

{"title":"Lipoprotein(a) in acute coronary syndrome: The case for universal screening","authors":"Cristina Gavina","doi":"10.1016/j.repc.2026.04.004","DOIUrl":"10.1016/j.repc.2026.04.004","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 227-229"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A three-pointed star in the ascending aorta","authors":"Hisato Takagi","doi":"10.1016/j.repc.2026.01.008","DOIUrl":"10.1016/j.repc.2026.01.008","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 261-262"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147464159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights into “Real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction”","authors":"Preeti Lamba","doi":"10.1016/j.repc.2026.04.001","DOIUrl":"10.1016/j.repc.2026.04.001","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 265-266"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health status and effects of spironolactone in people at high risk of heart failure: The Heart OMics in AGEing (HOMAGE) randomized trial","authors":"Inês Aguiar-Neves ,&nbsp;Sílvia O. Diaz ,&nbsp;João Pedro Ferreira ,&nbsp;Nicolas Girerd ,&nbsp;Pierpaolo Pellicori ,&nbsp;Beatrice Mariottoni ,&nbsp;Franco Cosmi ,&nbsp;Mark Hazebroek ,&nbsp;Job A.J. Verdonschot ,&nbsp;Joe Cuthbert ,&nbsp;Johannes Petutschnigg ,&nbsp;Stephane Heymans ,&nbsp;Jan A. Staessen ,&nbsp;Burkert Pieske ,&nbsp;Frank Edelmann ,&nbsp;Andrew L. Clark ,&nbsp;Patrick Rossignol ,&nbsp;Ricardo Fontes-Carvalho ,&nbsp;John G. Cleland ,&nbsp;Faiez Zannad","doi":"10.1016/j.repc.2025.12.010","DOIUrl":"10.1016/j.repc.2025.12.010","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Maintaining or improving quality of life (QoL) is an important therapeutic goal. QoL may be impaired before clinical onset of heart failure (HF). This study aims to describe changes in health status and the effect of spironolactone in people at risk of developing HF.</div></div><div><h3>Methods</h3><div>The Heart ‘OMics’ in AGEing (HOMAGE) trial randomized participants to spironolactone or usual care over a maximum follow-up of 9 months. Health status was assessed as a post-<em>hoc</em> secondary outcome using EQ-5D-3L (and derived EQ index), EQ-VAS and HOMAGE patient-reported symptom questionnaire.</div></div><div><h3>Results</h3><div>Health status was available on 98% of the 527 trial participants. The median age was 73 years, 25% were women. The EQ index ranged from 0.18 to 1; 42% of participants had an index of 1 (best possible health status). Participants with poorer health status (EQ index &lt;1) were predominantly women, had obesity, exertional breathlessness and lived alone. Independent baseline associations of deteriorating health status included: breathlessness on moderate exertion, smoking, higher serum galectin-3, higher E/e′ and higher left ventricular mass index at baseline. Left ventricular systolic function was associated with worse baseline QoL, but not with changes in EQ index or EQ-VAS during follow-up. Spironolactone did not influence health status during follow-up.</div></div><div><h3>Conclusions</h3><div>In people at risk of developing HF, obesity was associated with poorer health status. Worsening health status was more likely in patients with exertional breathlessness, echocardiographic signs of raised left ventricular filling pressures, and elevated galectin-3 levels at baseline. Spironolactone did not influence health status.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 243-253"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous closure of unusual cavity in a Fontan patient","authors":"Iñigo Anduaga ,&nbsp;Eduardo Flores-Umanzor ,&nbsp;Carlos Igor Morr-Verenzuela ,&nbsp;Juan M. Carretero Bellón ,&nbsp;Xavier Freixa","doi":"10.1016/j.repc.2025.12.009","DOIUrl":"10.1016/j.repc.2025.12.009","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 263-264"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147464174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What cannot be asked cannot be measured: Patient-reported outcomes and the diagnostic gap in heart failure","authors":"Rui Baptista","doi":"10.1016/j.repc.2026.04.003","DOIUrl":"10.1016/j.repc.2026.04.003","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 255-257"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk calculators: The everlasting search for the Holy Grail…","authors":"Luís Bronze","doi":"10.1016/j.repc.2026.03.003","DOIUrl":"10.1016/j.repc.2026.03.003","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 239-241"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147582489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of lipid profile and lipid-lowering therapy in the diabetic population of a primary care center according to cardiovascular risk category (SCORE2-Diabetes vs. SCORE)","authors":"André Cunha ,&nbsp;João Pedro Correia ,&nbsp;Joana Calheiros Lobo ,&nbsp;Francisca Botelho Elias ,&nbsp;Pedro Costa Leite ,&nbsp;Catarina Brazão ,&nbsp;Ana Lucas ,&nbsp;Dinis B. Loyens","doi":"10.1016/j.repc.2025.11.011","DOIUrl":"10.1016/j.repc.2025.11.011","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Cardiovascular diseases are among the leading causes of morbidity and mortality and represent a significant economic burden; having type 2 diabetes is a major risk factor. After identifying that a considerable proportion of patients with type 2 diabetes were not achieving their recommended LDL-C targets, a study was designed to assess LDL-C levels in relation to target values defined by cardiovascular risk (CVR) category and the lipid-lowering therapy (LLT) prescribed.</div></div><div><h3>Methods</h3><div>This cross-sectional study included a random sample of 245 patients with diabetes, aged 40–69 years, who had recent lipid profile and renal function tests and were being followed at a primary care (PC) center. Exclusion criteria were established for macrovascular disease, significant renal impairment, or microvascular complications in multiple territories.</div></div><div><h3>Results</h3><div>It was observed that 59.2% of patients had LDL-C levels above target, of whom over 75% were classified as high or very high risk. Among these, 27.6% were not receiving any LLT, and only 9% were being treated with high-intensity statins, either alone or in combination with ezetimibe. Among patients receiving this combination, 78.9% achieved target LDL-C levels. CVR category was higher in the SCORE model than the SCORE2-Diabetes in 56.7% of cases, significantly influencing the proportion of patients with LDL-C at target (20.0% vs. 40.8%, respectively; p=0.014).</div></div><div><h3>Conclusions</h3><div>Lipid-lowering therapy remains underutilized in patients with type 2 diabetes, particularly those at high and very high CVR, as over half fail to achieve LDL-C targets. Notably, the SCORE model appears to overestimate CVR compared with SCORE2-Diabetes.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 231-238"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147504075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to “Insights into real-world dapagliflozin treatment patterns in Portuguese patients with heart failure with reduced ejection fraction”","authors":"Aurora Andrade","doi":"10.1016/j.repc.2026.04.002","DOIUrl":"10.1016/j.repc.2026.04.002","url":null,"abstract":"","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Page 267"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147700614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) and acute coronary syndrome: Associations with sex, age and traditional cardiovascular risk factors","authors":"Catarina Carrapa ,&nbsp;Marta Leite ,&nbsp;Francisca Saraiva ,&nbsp;Sílvia O. Diaz ,&nbsp;António S. Barros ,&nbsp;Inês Neves ,&nbsp;Marta Almeida ,&nbsp;Diogo Santos Ferreira ,&nbsp;Gualter Santos Silva ,&nbsp;Francisco Sampaio ,&nbsp;Eduardo Vilela ,&nbsp;Ricardo Fontes-Carvalho","doi":"10.1016/j.repc.2025.11.012","DOIUrl":"10.1016/j.repc.2025.11.012","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Lipoprotein(a) [Lp(a)] is recognized as an independent risk factor for coronary disease owing to its atherogenic, proinflammatory, and prothrombotic properties. Current guidelines recommend a single measurement in adults to refine cardiovascular (CV) risk assessment. We aimed to characterize Lp(a) levels in patients with acute coronary syndrome (ACS) and explore associations with sex, age, comorbidities, and traditional cardiovascular risk factors.</div></div><div><h3>Methods</h3><div>We conducted a cross-sectional study of patients with ACS admitted to our center between January 2022 and December 2023, with Lp(a) measured at admission. Patients were stratified into two groups: Lp(a) &gt;100 nmol/L and ≤100 nmol/L. Demographic and clinical data, including traditional cardiovascular risk factors (dyslipidemia, diabetes mellitus, arterial hypertension, smoking, and obesity), were collected from hospital records. Chi-square and independent T or Mann–Whitney U tests were used to compare categorical and quantitative variables; linear regression analysis assessed associations between continuous Lp(a) values and independent variables.</div></div><div><h3>Results</h3><div>Among 903 patients admitted with ACS during the study period, Lp(a) was measured in 388 (42%). Median Lp(a) level was 62.0 [18.4, 153.8] nmol/L. Of these, 38.7% had Lp(a) &gt;100 nmol/L. Women had higher Lp(a) than men (p-trend=0.014). Lp(a) levels were similar across traditional cardiovascular risk factors categories. Among patients without traditional cardiovascular risk factors, women also had higher Lp(a) than men (p=0.003). Elevated Lp(a) was associated with a history of coronary artery disease (p-trend=0.003) and with treatment with high-intensity statins alone (p-trend=0.032) or in combination with ezetimibe (p-trend=0.014).</div></div><div><h3>Conclusions</h3><div>Lp(a) levels showed a heterogeneous distribution and were not associated with traditional cardiovascular risk factors or other lipid parameters. This reinforces Lp(a) as an independent risk factor, supporting active screening in patients with ACS, particularly in women not affected by traditional cardiovascular risk factors.</div></div>","PeriodicalId":48985,"journal":{"name":"Revista Portuguesa De Cardiologia","volume":"45 5","pages":"Pages 217-226"},"PeriodicalIF":1.6,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}